Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

4 results
Display

Cytapheresis in Patients with Severe Ulcerative Colitis after Failure of Intravenous Corticosteroid: A Long-Term Retrospective Cohort Study

Fukunaga K, Nagase K, Kusaka T, Hida N, Ohda Y, Yoshida K, Tozawa K, Kamikozuru K, Iimuro M, Nakamura S, Miwa H, Matsumoto

  • KMID: 1744239
  • Gut Liver.
  • 2009 Mar;3(1):41-47.
BACKGROUND/AIMS: Cytapheresis (CAP) is a novel strategy for ulcerative colitis (UC). However, there is insufficient data on the long-term outcome of UC patients who achieve remission by CAP. This study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adsorptive Granulocyte/Monocyte Apheresis for the Maintenance of Remission in Patients with Ulcerative Colitis: A Prospective Randomized, Double Blind, Sham-Controlled Clinical Trial

Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto

  • KMID: 2167411
  • Gut Liver.
  • 2012 Oct;6(4):427-433.
BACKGROUND/AIMS: Weekly granulocyte/monocyte adsorption (GMA) to deplete elevated and activated leucocytes should serve as a non-pharmacological intervention to induce remission in patients with ulcerative colitis (UC). This trial assessed the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of dietary protamine on lipid metabolism in rats

Hosomi R, Fukunaga K, Arai H, Kanda S, Nishiyama , Yoshida M

  • KMID: 2313481
  • Nutr Res Pract.
  • 2010 Dec;4(6):462-469.
Protamine has been widely used as a pharmaceutical product and natural food preservative. However, few studies have been conducted to assess the beneficial function of dietary protamine. This study examined...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Infliximab Therapy Impacts the Peripheral Immune System of Immunomodulator and Corticosteroid Naive Patients with Crohn's Disease

Kato K, Fukunaga K, Kamikozuru K, Kashiwamura S, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Yokoyama Y, Kikuyama R, Miwa H, Matsumoto

  • KMID: 2167272
  • Gut Liver.
  • 2011 Mar;5(1):37-45.
BACKGROUND/AIMS: Infliximab (IFX), an antibody to tumor necrosis factor, (TNF)-alpha has efficacy in treating Crohn's disease (CD). However, knowledge of the potential effects of IFX on patients' immune profiles is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr